CD274 and cancer: Furthermore, the phase 1 clinical trial consisting of 9 female patients with women’s cancer (ovarian, endometrial, and breast cancer) receiving a combination of durvalumab (PD-L1 inhibitor), cediranib (VEGFR1-3), and olaparib reported 67% clinical benefit rate (44% partial response and 33% stable disease ≥ 6 months) without dose-limiting toxicities [149].